Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Value in Oncology
Clinical Pathways and the Oncology Medical Home: First Steps to Value-Based Patient Care
By
Chase Doyle
Clinical Pathways
,
Value in Oncology
February 2016, Vol 7, No 1
With $137 billion and growing spent on treatment in the US healthcare annually, cancer care delivery poses a significant challenge. At a special session at ASH 2015 on new payment models, Michael Kolodziej, MD, National Medical Director for Oncology Solutions at Aetna, discussed pathways and the medical home as transitional solutions to value in cancer care.
Read Article
New Survey: Physicians Are Not Addressing Financial Distress in Patients with Multiple Myeloma
By
Chase Doyle
Value in Oncology
March 2016, Vol 7, No 2
Patients with multiple myeloma are making significant lifestyle trade-offs to manage the cost of healthcare, according to findings from the Cancer Experience Registry presented at ASH 2015. Joanne S. Buzaglo, PhD, Senior Vice President, Research and Training, Cancer Support Community, Philadelphia, PA, discussed survey results of patients with multiple myeloma who are assuming more costs, including direct costs (ie, copays and prescriptions) and indirect costs (ie, transportation costs and loss of income), which is leading to financial distress.
Read Article
Clinical Advances with Targeted Therapies for CLL Also Carry High Economic Burden
By
Chase Doyle
Value in Oncology
March 2016, Vol 7, No 2
Oral targeted therapies, such as ibrutinib (Imbruvica) and idelalisib (Zydelig), represent a major advance for patients with chronic lymphocytic leukemia (CLL) and have undoubtedly changed the treatment paradigm for this disease and the clinical outcomes.
Read Article
Value-Based Oncology Center of Excellence Model
By
Kelly Blair, MPA
Economics & Value
,
Value in Oncology
,
Value-Based Care
November 2015, Vol 6, No 10
“Centers of Excellence” (COEs) is not a new concept in healthcare. The underlying hypothesis is that providers who specialize in a particular procedure or service will produce superior, predictable outcomes. Payers have developed COE networks to manage cost and quality for complex medical conditions for more than 2 decades, steering volume to high-performing providers in exchange for discounted contractual rates. Under significant pressure to reduce the burden of cancer spending, payers are beginning to make bold network decisions, including narrowing networks, but they need precision tools to ensure that quality of care is uncompromised, and even improved, while reining in unsustainable cost trends.
Read Article
ASCO’s Value Framework: Is It All About the Drugs?
By
Avi Dor, PhD
;
Elizabeth Hoffler, MSW
;
Mandi Pratt-Chapman, MA
;
Eduardo Sotomayor, MD
Value in Oncology
,
ASCO’s Value Framework
October 2015, Vol 6, No 9
The American Society of Clinical Oncology (ASCO) recently issued its framework to assess the value of cancer treatment options in response to the major challenge of escalating healthcare costs in the United States.
Read Article
Communication with Oncologists, Not Cost, Tops Patients’ Value Priorities
By
Chase Doyle
Oncologist–Patient Communication
,
Value in Oncology
,
Value Peer-spectives
September 2015, Vol 6, No 8
The definition of value by patients with cancer does not necessarily coincide with other definitions by other stakeholders.
Read Article
The Push Toward Value-Based Payment for Oncology
By
Wayne Kuznar
Value in Oncology
July 2015, Vol 6, No 6
Chicago, IL—A transition from reimbursement based on volume to reimbursement based on value has begun to emerge, said speakers at the 2015 American Society of Clinical Oncology meeting in a session on payment reform. The transition will be clumsy, with competing and potentially mutually exclusive incentives.
Read Article
Value Propositions in Oncology: The Physician Perspective
By
Chase Doyle
Value in Oncology
,
Value Propositions
,
Value Peer-spectives
July 2015, Vol 6, No 6
Chicago, IL—The rising costs of cancer drugs and medical services, along with increased copays and high deductibles for patients, are adding a serious financial hardship to patients diagnosed with cancer, according to Neal J. Meropol, MD, Associate Director, Clinical Programs, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH.
Read Article
Anthem’s Clinical Pathways Demonstrate Value: The Payer Perspective
By
Chase Doyle
Clinical Pathways
,
Value in Oncology
July 2015, Vol 6, No 6
Chicago, IL—At the special session on value during the 2015 American Society of Clinical Oncology meeting, Jennifer Malin, MD, PhD, Staff Vice President for Clinical Strategy, Anthem, Thousand Oaks, CA, presented the payer perspective on value in cancer care. The role of the payer, Dr Malin said, is to balance different stakeholders’ values and needs at various time points.
Read Article
The Search for Value-Based Healthcare Delivery: The Agenda for Oncology
By
Chase Doyle
Value in Oncology
July 2015, Vol 6, No 6
Chicago, IL—The presidential keynote address at the 2015 American Society of Clinical Oncology meeting was presented by Michael E. Porter, PhD, MBA, Bishop William Lawrence University Professor, Harvard Business School, Boston, who started the value discussions a decade ago. A strong proponent of changing the healthcare system to focus on value, Dr Porter suggests that the fundamental purpose of healthcare is to deliver great outcomes with increasing efficiency, but achieving this goal requires more holistic thinking about delivery care as science.
Read Article
Page 6 of 7
1
2
3
4
5
6
7
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma